The US Etoricoxib market remained firm during the first half of May 2026 as rising production costs in major exporting countries such as China increased supplier quotations and import costs for US buyers. Higher feedstock prices, elevated crude oil and freight expenses, and increasing insurance premiums strengthened bullish sentiment across the Etoricoxib market. Importers continued securing cargoes despite higher offers due to stable pharmaceutical demand and tightening prompt availability. The strong market conditions in early May followed the upward trend observed throughout April, when import-driven supply met steady clinical and hospital demand amid increasing logistics and compliance costs. Chinese and Indian suppliers faced higher costs for key intermediates and extended regulatory review timelines, reducing the availability of prompt Etoricoxib shipments. At the same time, geopolitical tensions and vessel rerouting increased shipping delays and landed costs for imports into the United States. Demand remained primarily supported by hospital procurement, clinical research programs, and formulation manufacturers. Looking ahead, Etoricoxib prices are expected to witness further increases in the second half of May if freight costs, supply tightness, and offshore production expenses continue to rise.
The US Etoricoxib market moved higher during the first half of May 2026 as increased production costs in major exporting countries such as China pushed supplier quotations upward and raised import costs for US buyers. Market participants reported that higher feedstock and manufacturing expenses among Asian producers increased FOB offers for Etoricoxib cargoes, while elevated freight and insurance costs further strengthened landed prices in the United States. Importers continued accepting higher quotations due to steady pharmaceutical demand and tightening prompt availability, supporting bullish sentiment across the Etoricoxib market during early May.
The upward movement in the first half of May followed the strong price increases witnessed throughout April 2026, when import-driven supply met firm clinical and hospital demand against a backdrop of rising logistics and compliance expenses. According to ChemAnalyst, Etoricoxib (USP) CFR Houston prices increased to USD 82,530/MT in April from USD 76,770/MT previously, reflecting a monthly rise of 7.5%. During April, expedited shipments from China and India initially supported supply availability; however, rising container freight rates and extended quality-assurance reviews later tightened prompt cargo availability and increased landed costs for Etoricoxib imports into the US.
Demand for Etoricoxib remained primarily supported by the pharmaceutical sector, particularly clinical research programs, hospital pharmacies, and formulation manufacturers. Procurement activity for acute-pain and oncology-pain applications remained steady throughout April, sustaining routine call-offs from importers and specialist wholesalers. Retail demand for NSAID alternatives remained comparatively moderate, making institutional and hospital procurement the key driver behind the Etoricoxib price rally.
Supply-side pressures further reinforced the bullish market environment for Etoricoxib. Industry participants reported rising costs for benzene-derived halogenated intermediates and sulfuryl chloride, which increased production expenses and extended lead times for small-batch shipments. Although Chinese and Indian Etoricoxib producers maintained uninterrupted operating rates, exporters faced longer regulatory and documentation review timelines following intensified US compliance procedures, reducing the availability of prompt Etoricoxib cargoes.
In addition, ongoing geopolitical tensions and higher crude oil prices significantly increased freight costs and war-risk insurance premiums for shipments from Asia to the United States. Market participants noted that rerouting of vessels and longer transit times tightened effective supply availability and further increased landed costs for Etoricoxib imports.
During the first half of May, Etoricoxib prices remained firm as higher quotations from Chinese suppliers, elevated feedstock prices, and rising production expenses continued to increase import costs for US buyers. Sustained pharmaceutical demand also encouraged importers to accept higher Etoricoxib offers despite elevated logistics expenses.
Looking ahead to the second half of May, ChemAnalyst expects the Etoricoxib market to witness further price increases if current logistics disruptions, elevated freight charges, and tightening offshore supply persist. Continued strong demand from hospital and clinical procurement channels, combined with rising production costs among Asian exporters, is likely to maintain upward pressure on Etoricoxib prices in the near term, although the outlook remains sensitive to shipping conditions and regulatory developments.
